AI is rapidly transforming healthcare, especially in the realm of cardiovascular diagnostics. In November 2024, China’s National Health Commission, along with other agencies, released a guideline outlining 84 AI healthcare application scenarios.
As first reported by Guangming Online, RuiXin Medical recently introduced the AngioQFA 100 Coronary Artery Function Measurement System at the Eastern Cardiology Conference. This non-invasive system uses AI algorithms and external measurements to deliver Fractional Flow Reserve (FFR) and Index of Microcirculatory Resistance (IMR) scores within minutes—eliminating the risks and discomfort of traditional guidewire procedures.
The system marks a shift from morphology-based assessments like CT angiography to function-based diagnostics that better reflect real blood flow conditions. Founder Zheng Lingxiao, drawing on his cross-disciplinary background in engineering and medicine, led the development of this AI-powered solution, which combines 3D simulation, sensor chips, and proprietary algorithms. With more than 300 clinical trials supporting it, the AngioQFA 100 has demonstrated accuracy, sensitivity, and specificity above 95%.
RuiXin Medical employs a dual-wheel strategy of academic research and product innovation, holding over 200 patents and contributing to national guidelines for coronary diagnostics. The AngioQFA 100 system is already in clinical use across over 800 hospitals and has served more than 200,000 patients. A larger ecosystem has been built around it, covering the full treatment cycle from preoperative evaluation to postoperative management.
Looking ahead, the company plans to launch the world’s first fully automated PCI surgical robot, operated by voice command in a radiation-free environment. According to Zheng, this robot represents a new era where AI provides clinicians with superhuman “eyes,” “hands,” and “brains” to enhance precision, efficiency, and safety in cardiovascular care.
By merging cutting-edge AI with clinical expertise, RuiXin Medical is redefining how heart disease is diagnosed and treated in China, setting a new standard for precision, safety, and non-invasive care in cardiovascular medicine.
